2,194
Views
1
CrossRef citations to date
0
Altmetric
Diabetes

Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1055-1060 | Received 01 Jun 2023, Accepted 27 Jun 2023, Published online: 10 Jul 2023

References

  • IDF Diabetes Atlas | Tenth Edition. [Internet]; [cited 2023 Jan 25]. Available from https://diabetesatlas.org/.
  • IDF. Type 2 diabetes [Internet]; [cited 2023 Jan 25]. Available from: https://www.idf.org/aboutdiabetes/type-2-diabetes.html.
  • Wareham NJ, Herman WH. The clinical and public health challenges of diabetes prevention: a search for sustainable solutions. PLoS Med. 2016;13(7):e1002097. doi: 10.1371/journal.pmed.1002097.
  • World Health Organization. Diabetes [Internet]. 2022; [cited 2022 Nov 2]. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes.
  • Mitsios JP, Ekinci EI, Mitsios GP, et al. Relationship between glycated hemoglobin and stroke risk: a systematic review and meta‐analysis. J Am Heart Assoc. 2018;7:e007858.
  • van Wijngaarden RPT, Overbeek JA, Heintjes EM, et al. Relation between different measures of glycemic exposure and microvascular and macrovascular complications in patients with type 2 diabetes mellitus: an observational cohort study. Diabetes Ther. 2017;8(5):1097–1109. doi: 10.1007/s13300-017-0301-4.
  • Svensson E, Baggesen LM, Johnsen SP, et al. Early glycemic control and magnitude of HbA1c reduction predict cardiovascular events and mortality: population-Based cohort study of 24,752 metformin initiators. Diabetes Care. 2017;40(6):800–807. doi: 10.2337/dc16-2271.
  • Kontopantelis E, Springate DA, Reeves D, et al. Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study. Diabetologia. 2015;58(3):505–518. doi: 10.1007/s00125-014-3473-8.
  • Perez-Nieves M, Ivanova JI, Hadjiyianni I, et al. Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey. Curr Med Res Opin. 2017;33(10):1833–1842. doi: 10.1080/03007995.2017.1341403.
  • Melichova J, Sivco P, Rusnak M, et al. International evidence-based guidelines on hypertension and type 2 diabetes mellitus: a systematic review. J Public Health Res. 2023;12(1):227990362211469. doi: 10.1177/22799036221146913.
  • Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi: 10.1007/s00125-022-05787-2.
  • Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi: 10.1056/NEJMoa2107519.
  • Nederland Z. Farmacotherapeutisch Kompas [Internet]. Zorginstituut Nederland; [cited 2023 Feb 23]. Available from: https://www.farmacotherapeutischkompas.nl/.
  • Pharmacy Publishing | List of goods | pharmacist [Internet]; [cited 2023 Feb 23]. Available from https://warenverzeichnis.apoverlag.at/apotheker.
  • United Arab Emirates Ministry of Health and Prevention F. Registered Medical Product Directory [Internet]. Minist. Health Prev. – UAE; [cited 2023 Mar 10]. Available from: https://mohap.gov.ae/en/services/registered-medical-product-directory.
  • Vartotojui – tik saugūs ir efektyvūs vaistai! - Nekompensuojamųjų vaistinių preparatų kainynas [Internet. ]; [cited 2023 Feb 23]. Available from: https://www.vvkt.lt/index.php?2629283477.
  • Lingvay I, Cheng AYY, Levine JA, et al. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: a post hoc analysis of the SURPASS –1 to –5 studies. Diabetes Obes Metab. 2022;2022:dom.14943.
  • American diabetes association professional practice committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S113–S124.
  • Wharton S, Pedersen SD, Lau DCW, et al. Weight management in diabetes. Can J Diabetes. 2018;42: S124–S129. doi: 10.1016/j.jcjd.2017.10.015.
  • Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:645563. doi: 10.3389/fendo.2021.645563.
  • Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141.
  • Cardiovascular Benefit of Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg [Internet]. novoMEDLINK; [cited 2023 Feb 20]. Available from https://www.novomedlink.com/diabetes/products/treatments/ozempic/cardiovascular-benefit.html.
  • Cavallari I, Maddaloni E, Nusca A, et al. SGLT-2 inhibitors on top of current pharmacological treatments for heart failure: a comparative review on outcomes and cost effectiveness. Am J Cardiovasc Drugs. 2022;22(3):263–270. doi: 10.1007/s40256-021-00508-3.